Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene therapy study takes aim at prostate cancer

27.09.2006
Researchers at Baylor College of Medicine (BCM) are hoping a new gene therapy that takes a gene called RTVP-1 directly into the prostate tumor will prove effective in preventing recurrence of the disease.

The first phase of the study is designed to test the safety of the treatment and determine the proper dosage of gene, said Dr. Dov Kadmon, professor of urology at BCM. It will be carried out in the department of urology at BCM as well as at Ben Taub General Hospital, The Methodist Hospital and Michael E. DeBakey Veterans Affairs Medical Center.

"We are treating patients who are scheduled for a prostatectomy (prostate removal) but who also have a high risk that their disease will recur (or come back)," said Kadmon. "The operation itself is highly successful in eradicating local tumors (in the prostate)."

The design of the study is simple, said Kadmon.

... more about:
»BCM »Kadmon »RTVP-1 »prostate »urology

"One injection into the prostate that should take no more than 10 minutes, although patients will be monitored in a special unit of the hospital for 23 hours to make sure there are no side effects. After that, they come to the unit for a check-up once a week."

After about 30 days, the subjects undergo their surgery, which has already been scheduled, he said. He said the hope is that the gene therapy will reduce the risk that cancer will recur at or near the site of the tumor as well as in distant points in the body.

"We hope that by generating a systemic immune response, we are enabling the body to destroy prostate cancer cells that have moved elsewhere," he said. Kadmon and his colleagues plan to test six different doses of the gene.

The gene therapy involves attaching an inactivated adenovirus (related to viruses that cause respiratory infections) to the RTVP-1 gene. As the virus infects the tumor cells, it will introduce the gene into the cells as well. (RTVP stands for related to testes-specific, vespid and pathogenesis proteins.) The RTVP-1 gene was isolated in the laboratory of Dr. Timothy Thompson, also a professor of urology at BCM.

As Thompson began to study the gene, he found that it was a target for a tumor suppressor gene called p53, which is a major controller of cell activity in prostate and other cancers. He found that the human form of the gene is normally present in benign prostate or low grade tumor but is lost as the tumors become more malignant. "This characterized it as a tumor suppressor gene that is active in the prostate," said Kadmon.

When the gene is introduced into the tumors of animals lacking RTVP-1, it suppresses the formation of new blood vessels. It causes what is known as "apoptosis" or programmed cell death in prostate cancer cells and also activates the immune system to fight cancer cells.

"We are proceeding carefully, step-by-step," said Kadmon. He said they do not think the study presents a significant risk.

They will inject the virus-gene compound directly into the prostate. While there is a risk of infection with the injection, he said patients will receive antibiotics. Most patients will have some fever after the injection, but it can probably be handled with Tylenol.

Doctors will monitor patients after their surgery to determine the effect of the gene therapy on their disease.

Funding for the study, which will include as many as 36 subjects, comes from the National Cancer Institute and the Baylor Special Program for Research Excellence in Prostate Cancer that is NCI-funded.

Others involved in the study include Thompson, Dr. Brian J. Miles, BCM professor of urology; Dr. Adrian Gee, BCM professor of medicine and pediatrics in the section of hematology oncology; Dr. Thomas M. Wheeler, BCM professor of pathology and urology; Dr. Gustavo E. Ayala, BCM professor of pathology and urology; Dr. Martha P. Mims, BCM assistant professor of medicine in the section of hematology-oncology; and Dr. Teresa G. Hayes, BCM assistant professor of medicine, section of hematology-oncology.

Patients qualified to participate in this study are individuals diagnosed with high grade prostate cancer (Gleason grade 7 or higher), or who have a blood PSA level of 10ng/ml or higher and are contemplating surgery (radical prostatectomy). To register for the study or to obtain further information, patients may call 713-798-4895.

Gracie Gutierrez | EurekAlert!
Further information:
http://www.bcm.edu

Further reports about: BCM Kadmon RTVP-1 prostate urology

More articles from Life Sciences:

nachricht New photocatalyst speeds up the conversion of carbon dioxide into chemical resources
29.05.2017 | DGIST (Daegu Gyeongbuk Institute of Science and Technology)

nachricht Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>